$SNPX
Synaptogenix, Inc.

2021 Q3 Form 10-Q Financial Statement

#000110465921105204 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.093M $1.309M $2.569M
YoY Change -3.39% -49.06% 0.76%
% of Gross Profit
Research & Development $836.7K $986.3K $563.3K
YoY Change 103.93% 75.08% -64.12%
% of Gross Profit
Depreciation & Amortization $1.240K $1.240K $2.410K
YoY Change 0.81% -48.55%
% of Gross Profit
Operating Expenses $2.929M $2.295M $2.576M
YoY Change 13.7% -10.92% -37.31%
Operating Profit
YoY Change
Interest Expense $2.450K $1.330K $75.64K
YoY Change -63.97% -98.24% -24.36%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.927M -$2.294M -$4.270M
YoY Change -31.45% -46.28% 6.47%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.927M -$2.294M -$4.270M
YoY Change -31.45% -46.28% 6.47%
Net Earnings / Revenue
Basic Earnings Per Share $0.47 $0.58 $0.90
Diluted Earnings Per Share -$472.3K $0.58 $0.90
COMMON SHARES
Basic Shares Outstanding 6.136M 3.971M 4.755M
Diluted Shares Outstanding 6.197M 3.971M 4.755M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.29M $31.70M $30.25M
YoY Change 15.91% 4.8%
Cash & Equivalents $31.30M $31.70M $30.25M
Short-Term Investments
Other Short-Term Assets $1.046M $1.238M $589.6K
YoY Change -17.33% 110.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $32.34M $32.94M $30.84M
YoY Change 11.03% 6.81%
LONG-TERM ASSETS
Property, Plant & Equipment $18.49K $19.73K $24.68K
YoY Change -21.17% -20.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $18.49K $19.73K $24.68K
YoY Change -21.14% -20.08%
TOTAL ASSETS
Total Short-Term Assets $32.34M $32.94M $30.84M
Total Long-Term Assets $18.49K $19.73K $24.68K
Total Assets $32.36M $32.96M $30.87M
YoY Change 11.01% 6.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $935.4K $648.2K $967.6K
YoY Change -21.42% -33.02%
Accrued Expenses $71.95K $121.8K $99.95K
YoY Change -34.68% 21.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.007M $770.0K $1.068M
YoY Change -22.54% -27.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.007M $770.0K $1.068M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.007M $770.0K $1.068M
YoY Change -22.54% -27.88%
SHAREHOLDERS EQUITY
Retained Earnings -$9.906M -$6.979M
YoY Change
Common Stock $615.00 $604.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.35M $32.19M $29.80M
YoY Change
Total Liabilities & Shareholders Equity $32.36M $32.96M $30.87M
YoY Change 11.01% 6.79%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$2.927M -$2.294M -$4.270M
YoY Change -31.45% -46.28% 6.47%
Depreciation, Depletion And Amortization $1.240K $1.240K $2.410K
YoY Change 0.81% -48.55%
Cash From Operating Activities -$1.080M -$1.999M -$3.645M
YoY Change -66.78% -45.18% -52.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$5.410K
YoY Change -100.0% -154.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$5.410K
YoY Change -100.0% -45.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 672.8K 18.85M 16.52M
YoY Change 14.12% 32939.98%
NET CHANGE
Cash From Operating Activities -1.080M -1.999M -3.645M
Cash From Investing Activities 0.000 0.000 -5.410K
Cash From Financing Activities 672.8K 18.85M 16.52M
Net Change In Cash -407.4K 16.85M 12.87M
YoY Change -87.47% 30.96% -269.33%
FREE CASH FLOW
Cash From Operating Activities -$1.080M -$1.999M -$3.645M
Capital Expenditures $0.00 $0.00 -$5.410K
Free Cash Flow -$1.080M -$1.999M -$3.640M
YoY Change -66.78% -45.09% -52.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001571934
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Synaptogenix, Inc.
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6038798
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257579
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257579
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40458
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1585656
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
973
dei Local Phone Number
LocalPhoneNumber
242-0005
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SNPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
127445
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1238158
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
806289
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
snpx Net Change In Investment
NetChangeInInvestment
16519988
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1061096
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
snpx Warrants Issued During Period Value Issued For Services
WarrantsIssuedDuringPeriodValueIssuedForServices
267459
us-gaap Net Income Loss
NetIncomeLoss
-5469470
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6136302
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31702086
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5795055
CY2021Q2 us-gaap Assets Current
AssetsCurrent
32940244
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6728789
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19725
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22212
CY2021Q2 us-gaap Assets
Assets
32959969
CY2020Q4 us-gaap Assets
Assets
6751001
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
648164
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1260335
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
121809
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
352154
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
769973
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1612489
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6038798
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257579
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
604
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
126
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39168084
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6668859
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6978692
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1530473
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
32189996
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5138512
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32959969
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6751001
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
986280
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
600065
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2138060
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
993310
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1308893
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2407702
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3312306
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4622668
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
2295173
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3007767
us-gaap Operating Expenses
OperatingExpenses
5450366
us-gaap Operating Expenses
OperatingExpenses
5615978
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
1331
CY2020Q2 us-gaap Interest Income Other
InterestIncomeOther
75641
us-gaap Interest Income Other
InterestIncomeOther
2147
us-gaap Interest Income Other
InterestIncomeOther
146508
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
17418765
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2293842
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2932126
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5448219
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5469470
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2293842
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2932126
us-gaap Net Income Loss
NetIncomeLoss
-5448219
us-gaap Net Income Loss
NetIncomeLoss
-5469470
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.58
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
2.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.53
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
4.35
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3971200
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1257579
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3551600
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1257579
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
32175155
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
404280
CY2020Q2 snpx Warrants Issued During Period Value Issued For Services
WarrantsIssuedDuringPeriodValueIssuedForServices
150529
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2932126
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
29797838
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
29797838
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15409208
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-1529
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151552
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
52681
CY2021Q2 snpx Warrants Issued During Period Value Issued For Services
WarrantsIssuedDuringPeriodValueIssuedForServices
18156
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11271494
CY2021Q2 snpx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7582276
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2293842
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
32189996
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5138512
us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-1529
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
719791
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
396848
snpx Warrants Issued During Period Value Issued For Services
WarrantsIssuedDuringPeriodValueIssuedForServices
18156
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23784161
snpx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7582276
us-gaap Net Income Loss
NetIncomeLoss
-5448219
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
32189996
us-gaap Net Income Loss
NetIncomeLoss
-5448219
us-gaap Net Income Loss
NetIncomeLoss
-5469470
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3645433
snpx Parent Company Employee Benefits And Share Based Compensation
ParentCompanyEmployeeBenefitsAndShareBasedCompensation
1061096
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
719791
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
18156
snpx Issuance Of Stock And Warrants For Services
IssuanceOfStockAndWarrantsForServices
396848
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
267459
CY2020Q4 snpx Number Of Shares For Every Five Shares Of Common Stock Issuable Upon Exercise Of Warrants Held
NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld
1
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31700000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5800000
CY2021Q2 snpx Cash And Cash Equivalents Expected Amount At Financial Reporting Date
CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate
32100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2487
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2407
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
431869
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
95447
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-612171
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
554551
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-230345
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33971
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-137103
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1824037
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5585322
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5413
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5413
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23784161
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7582276
snpx Proceeds From Grant Funding
ProceedsFromGrantFunding
127445
snpx Payments In Lieu Shares For Reverse Stock Split
PaymentsInLieuSharesForReverseStockSplit
1529
snpx Net Transfer From To Parent
NetTransferFromToParent
16519988
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31492353
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16519988
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
25907031
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12869142
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5795055
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17382038
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31702086
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30251180
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 1 – Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Organization <span style="white-space:pre-wrap;">and </span>Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc. from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope would not own any equity interest in the Company, and we would operate independently from Neurotrope. On December 7, 2020 we became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”). Our shares of common stock are listed on The Nasdaq Capital Market under the symbol “SNPX.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 6, 2020, Neurotrope approved the final distribution ratio and holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrant holders as of November 30, 2020 (the “Spin-Off Record Date”) and received a pro rata distribution at the rate of (i) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock held, (ii) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the “Distribution”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Neurotrope Bioscience, Inc. was incorporated in Delaware on October 31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). The Company is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 4 - Related Party Transactions and Licensing / Research Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Spin-Off </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 1, 2020, Neurotrope, Petros Pharmaceuticals, Inc., a Delaware corporation (“Petros”), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), consummated the transactions (the “Mergers”) contemplated by that certain Agreement and Plan of Merger by and among the Company, Petros, Merger Sub 1, Merger Sub 2 and Metuchen, dated as of May 17, 2020 (the “ Merger Agreement”), as amended (the “Mergers”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a condition to the Mergers, Neurotrope approved a transaction (the “Spin-Off”), which became effective on December 7, 2020, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience, Inc., and (ii) holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants that were not amended and restated as of the Spin-Off Record Date received a pro rata distribution at the rate of (i) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock held, (ii) one share of Synaptogenix common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the “Distribution”). Any fractional shares were paid in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of Neurotrope’s amended and restated warrants to purchase 4,889,158 shares of Neurotrope common stock (the “A&amp;R Warrants”) received 977,831 warrants to purchase shares of Synaptogenix common stock upon the exercise of such A&amp;R Warrants held as of the Spin-Off Record Date (collectively, the “Spin-Off Warrants”). All the warrants have five year terms from December 2, 2020. See Note 8 – Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 7, 2020, the Company filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2021, the Company had approximately $31.7 million in cash and cash equivalents as compared to $5.8 million at December 31, 2020. The Company expects that its current cash and cash equivalents, $32.1 million as of the date of this quarterly report, which includes cash received during July and August of approximately $1.3 million consisting of cash received from exercise of investor warrants of approximately $800,000 plus reimbursement of trial expenses of approximately $500,000 from the NIH, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plan for Bryostatin-1, our novel drug targeting the activation of PKC epsilon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the current 2020 Phase 2 trial. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement,  and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”). Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize bryostatin for the treatment of AD. In June 2020, the Company entered into a supply agreement (the "Supply Agreement") with BryoLogyx Inc. ("BryoLogyx"), pursuant to which BryoLogyx agreed to be the Company's exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic Bryostatin-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company’s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our 2020 Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.</p>
CY2020Q4 snpx Number Of Shares For Every Five Common Shares Held
NumberOfSharesForEveryFiveCommonSharesHeld
1
CY2020Q4 snpx Number Of Shares For Every Five Shares Of Common Stock Issuable Upon Conversion Of Preferred Stock Held
NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld
1
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.01
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results. Changes in estimates resulting from weakness in the economic environment or other factors beyond the Company’s control could be material and would be reflected in the Company’s financial statements in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2021Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
9000000.0
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
22700000
CY2021Q2 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2020Q4 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
77800000
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19400000
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19400000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
250000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
250000
CY2021Q2 snpx Share Based Compensation Arrangement By Share Based Payment Award Aggregate Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateNumberOfSharesAuthorized
625000
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
0
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
0
CY2017Q1 snpx Annual License Maintenance Fee
AnnualLicenseMaintenanceFee
10000
CY2017Q1 snpx Commitment To Pay Fees
CommitmentToPayFees
2100000
snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
CY2020Q2 snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
CY2021Q2 snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
CY2020Q1 snpx Consulting Agreement Monthly Installment Fee
ConsultingAgreementMonthlyInstallmentFee
17500
CY2020Q4 snpx Issue Of Shares On Spin Off
IssueOfSharesOnSpinOff
1257579
CY2020Q4 snpx Spin Off Ratio
SpinOffRatio
0.20
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
snpx Number Of Votes Per Share Owned
NumberOfVotesPerShareOwned
1
CY2021Q1 snpx Aggregate Number Of Shares Authorized To Issue Under Purchase Agreement
AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement
2417242
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
123850
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.84
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
123850
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
77038
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y6M
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
978077
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1700000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
978077
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
52983
CY2020Q4 snpx Class Of Warrant Or Right Numerator Used To Determine Initial Exercise Price Of Spin Off Warrants
ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
2430000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
978077
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
6898451
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
941394
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
6935134
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
83334
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7600000
CY2020Q2 snpx Parent Company Employee Benefits And Share Based Compensation
ParentCompanyEmployeeBenefitsAndShareBasedCompensation
404280
CY2020Q2 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
150529
CY2020Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
554809
snpx Parent Company Employee Benefits And Share Based Compensation
ParentCompanyEmployeeBenefitsAndShareBasedCompensation
1061096
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
267459
snpx Contributions From Parent
ContributionsFromParent
16519988
us-gaap Labor And Related Expense
LaborAndRelatedExpense
17848543

Files In Submission

Name View Source Status
0001104659-21-105204-index-headers.html Edgar Link pending
0001104659-21-105204-index.html Edgar Link pending
0001104659-21-105204.txt Edgar Link pending
0001104659-21-105204-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snpx-20210630.xsd Edgar Link pending
snpx-20210630x10q.htm Edgar Link pending
snpx-20210630x10q_htm.xml Edgar Link completed
snpx-20210630xex31d1.htm Edgar Link pending
snpx-20210630xex31d2.htm Edgar Link pending
snpx-20210630xex32d1.htm Edgar Link pending
snpx-20210630xex32d2.htm Edgar Link pending
snpx-20210630_cal.xml Edgar Link unprocessable
snpx-20210630_def.xml Edgar Link unprocessable
snpx-20210630_lab.xml Edgar Link unprocessable
snpx-20210630_pre.xml Edgar Link unprocessable